Literature DB >> 17240105

Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).

Michael A Pfaller1, Helio S Sader, Ronald N Jones.   

Abstract

We evaluated the antimicrobial activity of daptomycin against 19,615 clinical strains consecutively collected by numerous centers located across the United States and Canada (2002-2005). Daptomycin was very active against all indicated species (>99% susceptible), with the highest MIC results being 2, 8, 0.5, and 1 microg/mL for staphylococci, enterococci, beta-hemolytic streptococci, and viridans group streptococci, respectively, and no significant loss in potency was observed over the period studied.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17240105     DOI: 10.1016/j.diagmicrobio.2006.10.007

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  17 in total

1.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Mechanisms of resistance to daptomycin in Enterococcus faecium.

Authors:  Clemente I Montero; Frida Stock; Patrick R Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

3.  Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Molly Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

5.  Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections.

Authors:  Andrew D G Van Praagh; Tongchuan Li; Shuxin Zhang; Anu Arya; Liping Chen; Xi-Xian Zhang; Shellie Bertolami; Lawrence I Mortin
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

6.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 7.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790

8.  Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.

Authors:  Cristina García-de-la-Mària; Juan M Pericas; Ana Del Río; Ximena Castañeda; Xavier Vila-Farrés; Yolanda Armero; Paula A Espinal; Carlos Cervera; Dolors Soy; Carlos Falces; Salvador Ninot; Manel Almela; Carlos A Mestres; Jose M Gatell; Jordi Vila; Asuncion Moreno; Francesc Marco; Jose M Miró
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

9.  The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

Authors:  P E Pertel; B I Eisenstein; A S Link; B Donfrid; E J A Biermann; P Bernardo; W J Martone
Journal:  Int J Clin Pract       Date:  2009-03       Impact factor: 2.503

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.